Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'- dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus